226 related articles for article (PubMed ID: 20615629)
21. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
22. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
Liao Z; Lee JJ; Komaki R; Gomez DR; O'Reilly MS; Fossella FV; Blumenschein GR; Heymach JV; Vaporciyan AA; Swisher SG; Allen PK; Choi NC; DeLaney TF; Hahn SM; Cox JD; Lu CS; Mohan R
J Clin Oncol; 2018 Jun; 36(18):1813-1822. PubMed ID: 29293386
[TBL] [Abstract][Full Text] [Related]
23. Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC.
Giaddui T; Chen W; Yu J; Lin L; Simone CB; Yuan L; Gong YU; Wu QJ; Mohan R; Zhang X; Bluett JB; Gillin M; Moore K; O'Meara E; Presley J; Bradley JD; Liao Z; Galvin J; Xiao Y
Radiat Oncol; 2016 May; 11():66. PubMed ID: 27142674
[TBL] [Abstract][Full Text] [Related]
24. Development and clinical validation of a robust knowledge-based planning model for stereotactic body radiotherapy treatment of centrally located lung tumors.
Visak J; McGarry RC; Randall ME; Pokhrel D
J Appl Clin Med Phys; 2021 Jan; 22(1):146-155. PubMed ID: 33285034
[TBL] [Abstract][Full Text] [Related]
25. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
[TBL] [Abstract][Full Text] [Related]
26. Limited Impact of Setup and Range Uncertainties, Breathing Motion, and Interplay Effects in Robustly Optimized Intensity Modulated Proton Therapy for Stage III Non-small Cell Lung Cancer.
Inoue T; Widder J; van Dijk LV; Takegawa H; Koizumi M; Takashina M; Usui K; Kurokawa C; Sugimoto S; Saito AI; Sasai K; Van't Veld AA; Langendijk JA; Korevaar EW
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):661-9. PubMed ID: 27681763
[TBL] [Abstract][Full Text] [Related]
27. Clinical implementation of intensity modulated proton therapy for thoracic malignancies.
Chang JY; Li H; Zhu XR; Liao Z; Zhao L; Liu A; Li Y; Sahoo N; Poenisch F; Gomez DR; Wu R; Gillin M; Zhang X
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):809-18. PubMed ID: 25260491
[TBL] [Abstract][Full Text] [Related]
28. Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.
Kesarwala AH; Ko CJ; Ning H; Xanthopoulos E; Haglund KE; O'Meara WP; Simone CB; Rengan R
Clin Lung Cancer; 2015 May; 16(3):237-44. PubMed ID: 25604729
[TBL] [Abstract][Full Text] [Related]
29. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy.
Li X; Kabolizadeh P; Yan D; Qin A; Zhou J; Hong Y; Guerrero T; Grills I; Stevens C; Ding X
Radiat Oncol; 2018 Feb; 13(1):35. PubMed ID: 29486782
[TBL] [Abstract][Full Text] [Related]
30. Small-spot intensity-modulated proton therapy and volumetric-modulated arc therapies for patients with locally advanced non-small-cell lung cancer: A dosimetric comparative study.
Liu C; Sio TT; Deng W; Shan J; Daniels TB; Rule WG; Lara PR; Korte SM; Shen J; Ding X; Schild SE; Bues M; Liu W
J Appl Clin Med Phys; 2018 Nov; 19(6):140-148. PubMed ID: 30328674
[TBL] [Abstract][Full Text] [Related]
31. Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans.
Wojcieszynski AP; Hill PM; Rosenberg SA; Hullett CR; Labby ZE; Paliwal B; Geurts MW; Bayliss RA; Bayouth JE; Harari PM; Bassetti MF; Baschnagel AM
Technol Cancer Res Treat; 2017 Jun; 16(3):366-372. PubMed ID: 28168936
[TBL] [Abstract][Full Text] [Related]
32. Technical Note: Treatment planning system (TPS) approximations matter - comparing intensity-modulated proton therapy (IMPT) plan quality and robustness between a commercial and an in-house developed TPS for nonsmall cell lung cancer (NSCLC).
Liu C; Yu NY; Shan J; Bhangoo RS; Daniels TB; Chiang JS; Ding X; Lara P; Patrick CL; Archuleta JP; DeWees T; Hu Y; Schild SE; Bues M; Sio TT; Liu W
Med Phys; 2019 Nov; 46(11):4755-4762. PubMed ID: 31498885
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
34. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
[No Abstract] [Full Text] [Related]
35. Fast arc delivery for stereotactic body radiotherapy of vertebral and lung tumors.
Ong CL; Verbakel WF; Dahele M; Cuijpers JP; Slotman BJ; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e137-43. PubMed ID: 22365628
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.
Nantavithya C; Gomez DR; Wei X; Komaki R; Liao Z; Lin SH; Jeter M; Nguyen QN; Li H; Zhang X; Poenisch F; Zhu XR; Balter PA; Feng L; Choi NC; Mohan R; Chang JY
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):558-563. PubMed ID: 29680255
[TBL] [Abstract][Full Text] [Related]
37. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
[TBL] [Abstract][Full Text] [Related]
38. The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation.
Cozzi L; Comito T; Loi M; Fogliata A; Franzese C; Franceschini D; Clerici E; Reggiori G; Tomatis S; Scorsetti M
Technol Cancer Res Treat; 2020; 19():1533033820980412. PubMed ID: 33287650
[TBL] [Abstract][Full Text] [Related]
39. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
[TBL] [Abstract][Full Text] [Related]
40. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer.
Koay EJ; Lege D; Mohan R; Komaki R; Cox JD; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1093-100. PubMed ID: 22543217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
